製剤技術とGMPの最先端技術情報

ロンザジャパン株式会社 受託製造開発事業部 Lonza Pharma & Biotech     

[細胞・遺伝子治療] Prevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail's Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases

2019/10/18

・ Strategic collaboration focuses on baculovirus/Sf9 expression system for Prevail's pipeline of novel AAV9-based gene therapy programs for patients with neurodegenerative diseases
・ Companies to partner on process development, analytical development, and large-scale manufacturing for late-stage clinical and commercial supply
・ Process development and manufacturing to be located in Lonza's cGMP facility in Houston, Texas
(リンク先より全文をご覧いただけます/英語)

企業情報

ロンザジャパン株式会社 受託製造開発事業部 Lonza Pharma & Biotech     

詳しく見る

このリリースに関連する商材情報

業界トピック

TOP